Lenka Mrázová

Lenka Mrázová

Auto-generated profile, based on publicly available information

Lenka Mrázová

Research Unit of Rare Diseases, Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2006 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
MHMartin Hřebíček
Martin Hřebíček
LMLenka Mrázová
Lenka Mrázová
VSVolkan Seyrantepe
Volkan Seyrantepe
SDStéphanie Durand
Stéphanie Durand
NRNicole M. Roslin
Nicole M. Roslin
APAlexey Pshezhetsky
Alexey Pshezhetsky

29 January 2009 in Human Mutation
Verified
Journal Article
Open access
PDF file
MFMatthew Feldhammer
Matthew Feldhammer
SDStéphanie Durand
Stéphanie Durand
LMLenka Mrázová
Lenka Mrázová
RBRenée-Myriam Boucher
Renée-Myriam Boucher
RLRachel Laframboise
Rachel Laframboise
APAlexey Pshezhetsky
Alexey Pshezhetsky
Mucopolysaccharidosis (MPS) type IIIC or Sanfilippo syndrome type C is a rare autosomal recessive disorder caused by the deficiency of the lysosomal membrane enzyme, heparan sulfate acetyl‐CoA (AcCoA): α‐glucosaminide N‐acetyltransferase (HGSNAT; EC 2.3.1.78), which catalyzes transmembrane acetylation of the terminal glucosamine residues of heparan sulfate prior to their hydrolysis by α‐N‐acetylglucosaminidase. Lysosomal storage of undegraded heparan sulfate in the cells of affected patients leads to neuronal death, causing neurodegeneration and severely impaired development accompanied by mild visceral and skeletal abnormalities, including mild dwarfism, coarse facies, and joint stiffness. To date, 50 HGSNAT mutations have been identified in MPS IIIC patients: 40 were previously published and 10 novel mutations are reported here. The mutations span the entire structure of the gene and include 13 splice‐site mutations, 11 insertions and deletions, 8 nonsense mutations, and 18 missense mutations (http://chromium.liacs.nl/LOVD2/home.php?select_db=HGSNAT). In addition, four polymorphisms result in amino acid changes that do not affect activity of the enzyme. In this work we discuss the spectrum of MPS IIIC mutations, their clinical presentation and distribution within the patient population, and speculate how the mutations may affect the structure and function of HGSNAT. Hum Mutat 30, 918–925, 2009.

1 July 2017 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
SGSarah Catharina Grünert
Sarah Catharina Grünert
SSSonja Marina Schlatter
Sonja Marina Schlatter
RSRobert Niklas Schmitt
Robert Niklas Schmitt
CGCorinne Gemperle-Britschgi
Corinne Gemperle-Britschgi
LMLenka Mrázová
Lenka Mrázová
JSJörn Oliver Sass
Jörn Oliver Sass

28 June 2024 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
BKBarbora Judita Kasperova
Barbora Judita Kasperova
MMMilos Mraz
Milos Mraz
PSPetr Svoboda
Petr Svoboda
DHDaniel Hlaváček
Daniel Hlaváček
HKHelena Kratochvilova
Helena Kratochvilova
MHMartin Haluzík
Martin Haluzík
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) are glucose-lowering agents used for the treatment of type 2 diabetes mellitus, which also improve heart failure and decrease the risk of cardiovascular complications. Epicardial adipose tissue (EAT) dysfunction was suggested to contribute to the development of heart failure. We aimed to elucidate a possible role of changes in EAT metabolic and inflammatory profile in the beneficial cardioprotective effects of SGLT-2i in subjects with severe heart failure. Methods: 26 subjects with severe heart failure, with reduced ejection fraction, treated with SGLT-2i versus 26 subjects without treatment, matched for age (54.0 ± 2.1 vs. 55.3 ± 2.1 years, n.s.), body mass index (27.8 ± 0.9 vs. 28.8 ± 1.0 kg/m2, n.s.) and left ventricular ejection fraction (20.7 ± 0.5 vs. 23.2 ± 1.7%, n.s.), who were scheduled for heart transplantation or mechanical support implantation, were included in the study. A complex metabolomic and gene expression analysis of EAT obtained during surgery was performed. Results: SGLT-2i ameliorated inflammation, as evidenced by the improved gene expression profile of pro-inflammatory genes in adipose tissue and decreased infiltration of immune cells into EAT. Enrichment of ether lipids with oleic acid noted on metabolomic analysis suggests a reduced disposition to ferroptosis, potentially further contributing to decreased oxidative stress in EAT of SGLT-2i treated subjects. Conclusions: Our results show decreased inflammation in EAT of patients with severe heart failure treated by SGLT-2i, as compared to patients with heart failure without this therapy. Modulation of EAT inflammatory and metabolic status could represent a novel mechanism behind SGLT-2i-associated cardioprotective effects in patients with heart failure.

12 September 2007 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
AŠAnna Šedivá
Anna Šedivá
CSC. I. Edvard Smith
C. I. Edvard Smith
AAA. Charlotta Asplund
A. Charlotta Asplund
JHJan Hadač
Jan Hadač
AJAleš Janda
Aleš Janda
HOHans D. Ochs
Hans D. Ochs

12 November 2024 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
MŽMartina Živná
Martina Živná
GDGabriela Dostálová
Gabriela Dostálová
VBVeronika Barešová
Veronika Barešová
DMDita Mušálková
Dita Mušálková
KSKlára Svojšová
Klára Svojšová
SKStanislav Kmoch
Stanislav Kmoch
Key Points: The clinical significance of a number of missense variants of α-galactosidase A is often ambiguous. Defective proteostasis of some missense α-galactosidase A variants induced chronic endoplasmic reticulum stress and the unfolded protein response. Endoplasmic reticulum stress and the unfolded protein response may explain clinical manifestations of non-classic Fabry disease. Background: Classic Fabry disease is caused by GLA mutations that result in loss of enzymatic activity of α-galactosidase A, lysosomal storage of globotriaosylceramide, and a resulting multisystemic disease. In non-classic Fabry disease, patients have some preserved α-galactosidase A activity and a milder disease course. Heterozygous female patients may also be affected. While Fabry disease pathogenesis has been mostly attributed to catalytic deficiency of mutated α-galactosidase A, lysosomal storage, and impairment of lysosomal functions, other pathogenic factors may contribute, especially in nonclassic Fabry disease. Methods: We characterized the genetic, clinical, biochemical, molecular, cellular, and organ pathology correlates of the p.L394P α-galactosidase A variant that was identified initially in six individuals with kidney failure by the Czech national screening program for Fabry disease and by further screening in an additional 24 family members. Results: Clinical findings in affected male patients revealed a milder clinical course, with approximately 15% residual α-galactosidase A activity with normal plasma lyso-globotriaosylceramide levels and abnormally low ratio of these values. None of the four available kidney biopsies showed lysosomal storage. Laboratory investigations documented intracellular retention of mutated α-galactosidase A with resulting endoplasmic reticulum stress and the unfolded protein response, which were alleviated with BRD4780, a small molecule clearing misfolded proteins from the early secretory compartment. We observed similar findings of endoplasmic reticulum stress and unfolded protein response in five kidney biopsies with several other classic and non-classic Fabry disease missense α-galactosidase A variants. Conclusions: We identified defective proteostasis of mutated α-galactosidase A resulting in chronic endoplasmic reticulum stress and unfolded protein response of α-galactosidase A expressing cells as a contributor to Fabry disease pathogenesis.